The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.
A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Interpreting Clinical Trial Headlines and Announcements in Fragile X Syndrome — Presentation
Explore examples of recent announcements and headlines focused on treatment development in Fragile X syndrome. Presented by Elizabeth Berry-Kravis, MD, PhD, and Craig A. Erickson, MD.
The Progression of Pathology in Longitudinally Followed Patients with FXTAS — Presentation
Learn in this webinar the pathological progression of several longitudinally followed patients with FXTAS at the UC Davis Fragile X Research and Treatment Center.